✦ LIBER ✦

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials

✍ Scribed by Argiris, A.; Li, S.; Ghebremichael, M.; Egloff, A. M.; Wang, L.; Forastiere, A. A.; Burtness, B.; Mehra, R.

Book ID: 121844009
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 207 KB
Volume: 25
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu167

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel and irinotecan in recurrent or

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the Eastern Cooperative Oncology Group

✍ Athanassios Argiris; Ashley Buchanan; Bruce Brockstein; Jill Kolesar; Musie Gheb 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views

Phase III Randomized, Placebo-Controlled

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

✍ Argiris, A.; Ghebremichael, M.; Gilbert, J.; Lee, J.-W.; Sachidanandam, K.; Kole 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 328 KB

Prognostic factors and long-term survivo

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck : An analysis of two Eastern Cooperative Oncology Group randomized trials

✍ Athanassios Argiris; Yi Li; Arlene Forastiere 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

Prospective, randomized comparison of ch

Prospective, randomized comparison of chemotherapy of recurrent or metastatic squamous cancer of the head and neck (SCH&N) with methotrexate (M) versus methotrexate, bleomycin (B) and cis-diamminedichloroplatinum II (D) — an Eastern cooperative oncology group study

✍ Steven E. Vog; David Schoenfeld; Barry H. Kaplan; Harvey Lerner 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 107 KB

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr

A phase II trial of trastuzumab plus wee

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

✍ Stacy Moulder; Hailun Li; Molin Wang; William J. Gradishar; Edith A. Perez; Jose 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 250 KB